Descripción del proyecto
Un novedoso tratamiento antimetastásico contra el cáncer de mama triple negativo
El cáncer de mama triple negativo (CMTN) es un tipo de cáncer de mama agresivo con gran propensión a la metástasis. En este tipo de neoplasia no se expresan los receptores de los estrógenos y, por lo tanto, existen menos opciones de tratamiento específicas y eficaces. El equipo del proyecto CanceRusolution, financiado con fondos europeos, ha concebido un fármaco citostático dirigido al citoesqueleto de las células del CMTN, que frena su potencial metastásico y, por tanto, su agresividad. Los investigadores tienen previsto probar el tratamiento en un modelo animal de CMTN y realizar un análisis farmacocinético. La mejora del tratamiento hasta el nivel clínico allanará el camino hacia sus pruebas clínicas, con repercusiones significativas para la futura gestión del CMTN.
Objetivo
R-nuucell is developing a new drug to treat Triple Negative Breast Cancer (TNBC) for which there is not any specific and efficient treatment in the market, making this disease an unmet clinical need.
The aggressivity of TNBC is due to the easiness of its metastization expanding the cancer through the body inevitably leading to death. So far, we gathered a set of results showing the antimetastatic potential of our new drug which mode of action would, conceptually, be able to eliminate the deadliest feature of cancer cells – their ability to invade and metastasize. This happens because the target of our drug is the cells’ foundation (ie the cytoskeleton). Thus, destroying the cytoskeleton of cells is like shaking the foundations of a house, it will be tumble-down!
With the Women TechEU program we will consolidate the proof-of-concept of the drug’s efficiency against metastases through two sets of in vivo studies in nude mice, and we will start the pre-clinical studies by performing pharmacokinetics (drug absorption, distribution, metabolism and excretion). Also, in view of the natural future development of our drug we will start to develop its synthesis scale-up from the milligram to the multigram scale.
Women TechEU program mentoring and coaching will be also key to consolidate our business plan and to approach partners and investors towards a fundraising Level A in the near future. This level of funding (~1 M€) will enable to finish our pre-clinical studies and place R-nuucell in the position to license its international patent, one of the company’s assets (PT108082B, EA038640B1, EP3227307B1, CN107466297B, JP6726678B2, US15/533,289, under examination on Canada, Brazil and India), to a pharmaceutical company using a “business-to-business” strategy.
Ámbito científico
Programa(s)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-AG-LS - HORIZON Lump Sum GrantCoordinador
1749-016 LISBOA
Portugal
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.